Overview

A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies

Status:
Completed

Trial end date:
2004-05-01

Target enrollment:

Participant gender:

Summary

This is a Phase IIIb, open label, uncontrolled, multicenter study designed to evaluate the safety and tolerability of 12 weeks of subcutaneously administered efalizumab in subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy and may also be receiving topical therapies, PUVA, or UVB phototherapy during the efalizumab treatment period.

Phase:

Phase 3

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal